This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCoy, C. Articles by Cornwell, M. M. Search for Related Content PubMed PubMed Citation Articles by McCoy, C. Articles by Cornwell, M. M.

The Wilms’ Tumor Suppressor, WT1, Inhibits 12-O-Tetradecanoylphorbol-13-acetate Activation of the Multidrug Resistance-1 Promoter¹

Fred Hutchinson Cancer Research Center, Seattle, Washington 98109

Overexpression of P-glycoprotein, the product of the multidrug resistance-1 (MDR1) gene, is associated with treatment failure in some hematopoietic tumors. Although expression of P-glycoprotein in normal hematopoietic cells is tightly regulated during hematopoietic differentiation, its aberrant overexpression in hematopoietic malignancies occurs at the transcriptional level. We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Cell. Biol., 15: 6100–6108, 1995). We demonstrate here that the Wilms’ tumor (WT) suppressor, WT1, a member of the EGR family, inhibits the response of the MDR1 promoter to TPA in K562 cells. Inhibition is likely a direct effect of WT1 binding to the MDR1 promoter because: (a) WT1 expression does not inhibit the increase in EGR1 after TPA treatment; (b) inhibition by WT1 requires the zinc finger domain; (c) WT1 binds to MDR1 promoter sequences that bind EGR1 and are responsive to TPA; and (d) there is an inverse correlation between WT1 protein expression and MDR1 expression and promoter activity. These results suggest that the MDR1 gene is a target for regulation by WT1 and suggest mechanisms by which MDR1 may be regulated by WT1 and EGR1 during normal and aberrant hematopoiesis.

This article has been cited by other articles:

				M. J. Perugorria, J. Castillo, M. U. Latasa, S. Goni, V. Segura, B. Sangro, J. Prieto, M. A. Avila, and C. Berasain Wilms' Tumor 1 Gene Expression in Hepatocellular Carcinoma Promotes Cell Dedifferentiation and Resistance to Chemotherapy Cancer Res., February 15, 2009; 69(4): 1358 - 1367. [Abstract] [Full Text] [PDF]

				H. Shen, W. Xu, Z. Wu, H. Tang, Y. Xie, and X. Zhong Down-regulation of WT1/+17AA gene expression using RNAi and modulating leukemia cell chemotherapy resistance Haematologica, September 1, 2007; 92(9): 1270 - 1272. [Abstract] [Full Text] [PDF]

				D. Xu, D. Ye, M. Fisher, and R. L. Juliano Selective Inhibition of P-glycoprotein Expression in Multidrug-Resistant Tumor Cells by a Designed Transcriptional Regulator J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 963 - 971. [Abstract] [Full Text] [PDF]

				K. W. Scotto and R. A. Johnson Transcription of MDR1: A Therapeutic Target Mol. Interv., June 1, 2001; 1(2): 117 - 125. [Abstract] [Full Text] [PDF]

				V. V. Bartsevich and R. L. Juliano Regulation of the MDR1 Gene by Transcriptional Repressors Selected Using Peptide Combinatorial Libraries Mol. Pharmacol., July 1, 2000; 58(1): 1 - 10. [Abstract] [Full Text]

				Z. Hu, S. Jin, and K. W. Scotto Transcriptional Activation of the MDR1 Gene by UV Irradiation. ROLE OF NF-Y AND Sp1 J. Biol. Chem., January 28, 2000; 275(4): 2979 - 2985. [Abstract] [Full Text] [PDF]